1728. Minimal factor XIII activity level to prevent major spontaneous bleeds 1737. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in…
2115. Effect of late prophylaxis in hemophilia on joint status a randomized trial 2125. Reversal of apixaban anticoagulation by four factor prothombin complex concetrates in healthy subjects a ran…
1241. Novel insight into the regulation of coagulation by factor V isoforms, tissue factors V isoforms tissue factor pathway inhibitor and protein s 1251. Diagnosis of acute pulmonary embolism 12…
1055. Incidence of intracranial bleeds in new users of low-dose aspirin a cohort study using the health improvement 1065. Predictive performance of the CHA2DS2 VASc rule in atrial fibrillation a …
1443. Balancing risk and benefit in venous thromboembolism trials concept for a bivariate endpoint trial design and analytic approach 1449. Hemophillia A and hemopholia B focus on arthropathy and …
2092. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism systematic review and meta analysis 2103. Pulmonary embolism severity …
1683. Benefits and challenges of going abroad for research or clinical training 1685. Protamine (heparin) induced trombocytopenia 1696. Current and future perspectives in imaging of venous 171…
1905. Reflections on scientific collaboration between basic researches and clinicians 1908. Coagulation and non coagulation effects of thrombin 1917. Assesment of endothelial damage and cardiac i…
3. Inferior vena cava filters 13. Von willebrand factor and angiogenesis basic and applied issues 21. Association of stroke risk biomarkers with stroke symptomps the reason for geoghrafic and rac…
213. Inorganic polyphospate a key modulator of inflammation 219. Physiologic and pathophysiological roles of interaction between C type lectin like receptor 2 and podoplanin 230. The posthromboti…